James E Sharman1, Pierre Boutouyrie2, Stéphane Laurent2. 1. Menzies Institute for Medical Research, University of Tasmania, Private Bag 23, Hobart, 7000, Australia. James.Sharman@utas.edu.au. 2. Departments of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France.
Abstract
PURPOSE OF REVIEW: The purpose of the review is to examine whether measurement of aortic stiffness could be especially value-adding for risk stratification and treatment among patients with resistant hypertension (RH). RECENT FINDINGS: Adverse arterial remodeling and increased aortic stiffness is associated with RH, and it may be of additional clinical benefit to measure aortic stiffness in these patients. However, there is insufficient evidence to determine whether aortic stiffness is excessively high relative to the level of blood pressure (BP) among people with RH. This issue needs resolution as it could help refine management decisions guided by aortic stiffness. If conventional antihypertensive therapy fails to lower BP in patients with RH, there is good rationale for effectiveness of spironolactone as add on therapy, and this should also improve aortic stiffness. Lifestyle intervention with exercise and diet should be additionally efficacious towards improving BP and aortic stiffness in patients with RH, but there is limited data in this patient population. For better characterization on the effects of BP treatment on aortic stiffness, measures of central aortic BP may help refine management decisions above and beyond conventional arm cuff BP. There is strong evidence to support the use of aortic stiffness as a tool to aid risk stratification in hypertension management. Although there is a theoretical basis for special additional benefit of measuring aortic stiffness in patients with RH (as distinct from uncomplicated hypertension), at this time, there is inadequate data available to make definitive conclusions and is an area for future investigation.
PURPOSE OF REVIEW: The purpose of the review is to examine whether measurement of aortic stiffness could be especially value-adding for risk stratification and treatment among patients with resistant hypertension (RH). RECENT FINDINGS: Adverse arterial remodeling and increased aortic stiffness is associated with RH, and it may be of additional clinical benefit to measure aortic stiffness in these patients. However, there is insufficient evidence to determine whether aortic stiffness is excessively high relative to the level of blood pressure (BP) among people with RH. This issue needs resolution as it could help refine management decisions guided by aortic stiffness. If conventional antihypertensive therapy fails to lower BP in patients with RH, there is good rationale for effectiveness of spironolactone as add on therapy, and this should also improve aortic stiffness. Lifestyle intervention with exercise and diet should be additionally efficacious towards improving BP and aortic stiffness in patients with RH, but there is limited data in this patient population. For better characterization on the effects of BP treatment on aortic stiffness, measures of central aortic BP may help refine management decisions above and beyond conventional arm cuff BP. There is strong evidence to support the use of aortic stiffness as a tool to aid risk stratification in hypertension management. Although there is a theoretical basis for special additional benefit of measuring aortic stiffness in patients with RH (as distinct from uncomplicated hypertension), at this time, there is inadequate data available to make definitive conclusions and is an area for future investigation.
Entities:
Keywords:
Blood vessels; Cardiovascular systems; Drug therapies; Hemodynamic; Pharmacotherapies
Authors: P Boutouyrie; C Bussy; D Hayoz; J Hengstler; N Dartois; B Laloux; H Brunner; S Laurent Journal: Circulation Date: 2000-06-06 Impact factor: 29.690
Authors: Felix Mahfoud; Michael Böhm; Michel Azizi; Atul Pathak; Isabelle Durand Zaleski; Sebastian Ewen; Kostantinos Tsioufis; Bert Andersson; Peter J Blankestijn; Michel Burnier; Gilles Chatellier; Sameer Gafoor; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Thomas Felix Lüscher; Melvin D Lobo; Chaim Lotan; Gianfranco Parati; Josep Redon; Luis Ruilope; Isabella Sudano; Christian Ukena; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns; Thomas Zeller; Roland E Schmieder Journal: Eur Heart J Date: 2015-05-18 Impact factor: 29.983
Authors: Philip M Mottram; Brian Haluska; Rodel Leano; Diane Cowley; Michael Stowasser; Thomas H Marwick Journal: Circulation Date: 2004-07-26 Impact factor: 29.690
Authors: Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown Journal: Lancet Date: 2015-09-20 Impact factor: 79.321
Authors: Tess De Bruyne; Bieke Steenput; Lynn Roth; Guido R Y De Meyer; Claudia Nunes Dos Santos; Kateřina Valentová; Maija Dambrova; Nina Hermans Journal: Nutrients Date: 2019-03-08 Impact factor: 5.717